Champions Oncology (NASDAQ:CSBR) Stock Price Passes Below Two Hundred Day Moving Average – Should You Sell?

Champions Oncology, Inc. (NASDAQ:CSBR)’s share price crossed below its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of $6.37 and traded as low as $5.70. Champions Oncology shares last traded at $5.85, with a volume of 20,938 shares.

Wall Street Analyst Weigh In

Separately, Weiss Ratings downgraded Champions Oncology from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Friday, May 22nd. One analyst has rated the stock with a Sell rating, According to MarketBeat, the stock presently has an average rating of “Sell”.

Champions Oncology Stock Down 0.3%

The company has a market capitalization of $81.26 million, a PE ratio of -36.56 and a beta of 0.42. The stock has a 50-day moving average of $5.97 and a 200 day moving average of $6.37.

Institutional Trading of Champions Oncology

A number of large investors have recently bought and sold shares of CSBR. XTX Topco Ltd purchased a new stake in Champions Oncology in the second quarter worth $103,000. Essex Investment Management Co. LLC purchased a new stake in Champions Oncology in the fourth quarter worth $126,000. Jane Street Group LLC purchased a new stake in Champions Oncology in the first quarter worth $200,000. Goldman Sachs Group Inc. purchased a new stake in Champions Oncology in the first quarter worth $201,000. Finally, Acadian Asset Management LLC increased its position in Champions Oncology by 28.7% in the first quarter. Acadian Asset Management LLC now owns 39,511 shares of the biotechnology company’s stock worth $341,000 after buying an additional 8,814 shares during the last quarter. 41.30% of the stock is owned by hedge funds and other institutional investors.

About Champions Oncology

Champions Oncology, Inc engages in the development and sale of technology solutions and products to personalize the development and use of oncology drugs. Its technology platform, TumorGraft, is a novel approach to personalizing cancer care based upon the implantation of human tumors in immune-deficient mice. It uses its technology to offer solutions to Translational Oncology Solutions, which includes pharmaceutical and biotechnology companies; and Personalized Oncology, which assists physicians in developing personalized treatment options for their cancer patients.